DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9,512,236 B2 Adams Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9,512,236 B2 Adams Et Al USOO951 2236B2 (12) United States Patent (10) Patent No.: US 9,512,236 B2 Adams et al. (45) Date of Patent: Dec. 6, 2016 (54) AMINO ACID SEQUENCES DIRECTED (52) U.S. Cl. AGAINST GPCRS AND POLYPEPTIDES CPC ......... C07K 16/468 (2013.01); C07K 16/2866 COMPRISING THE SAME FOR THE (2013.01); C07K 16/2869 (2013.01); C07K TREATMENT OF GPCR-RELATED 231 7/22 (2013.01); C07K 23.17/31 (2013.01); DISEASES AND DISORDERS C07K 23.17/34 (2013.01); C07K 23.17/35 (2013.01); C07K 2317/92 (2013.01) (71) Applicant: Ablynx N.V., Zwijnaarde (BE) (58) Field of Classification Search None (72) Inventors: Hendrik Adams, Rotterdam (NL); See application file for complete search history. Michael John Scott Saunders, Brussels (BE); Johannes Joseph Wilhelmus De Haard, Oudelande (56) References Cited (NL); Christophe Blanchetot, Destelbergen (BE); Martine Smit, U.S. PATENT DOCUMENTS Amsterdam (NL); Regorius Leurs, 8,937,164 B2 1/2015 Descamps et al. Amsterdam (NL); Sven Jahnichen, 9,212,226 B2 12/2015 Blanchetot et al. Schwarme (DE); Peter Vanlandschoot, 2002/0106.739 A1 8/2002 Oakley et al. 2004/0170634 A1 9, 2004 Burns et al. Bellem (BE); Francis Descamps, 2007/0167443 A1 7/2007 Melikian et al. Roeselare (BE); Maria Gonzalez 2010.0062004 A1 3/2010 Adams et al. Pajuelo, Porto (PT); Pascal Gerard 2011/0206660 A1 8/2011 Blanchetot et al. Merchiers, Tielen (BE); Catelijne 2011/0262438 A1 10/2011 Descamps et al. Stortelers, Ghent (BE); Philippe Van 2014/0178390 A1 6/2014 Descamps et al. Rompaey, Melle (BE); David Andre 2014/0227 270 A1 8/2014 Descamps et al. Baptiste Maussang-Detaille, Rotterdam (NL); Maarten Van Roy, Zwijnaarde FOREIGN PATENT DOCUMENTS (BE) EP O 368 684 A1 5, 1990 EP O 542 810 5, 1993 (73) Assignee: Ablynx N.V., Zwijnaarde (BE) EP 1316 801 A1 9, 2002 JP 2008-539772 A 11/2008 (*) Notice: Subject to any disclaimer, the term of this JP 2008-539775 A 11/2008 patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/650,600 No Author Listed Nature Reviews Drug Discovery GPCR Ques (22) Filed: Oct. 12, 2012 tionnaire Participants. The state of GPCR research in 2004. Nat Rev Drug Discov. Jul. 2004:3(7):575, 577-626. (65) Prior Publication Data (Continued) US 2013/O 130379 A1 May 23, 2013 Primary Examiner — Ruixiang Li Related U.S. Application Data (74) Attorney, Agent, or Firm — Wolf, Greenfield & (63) Continuation-in-part of application No. 12/520,299. Sacks, P.C. filed as application No. PCT/EP2007/064243 on Dec. 19, 2007, now abandoned, application No. (57) ABSTRACT 13/650,600, which is a continuation-in-part of application No. 12/992,982, filed as application No. The present invention relates to amino acid sequences that PCT/EP2009/056026 on May 18, 2009, now Pat. No. are directed against G-protein coupled receptors (GPCRs), 9,212.226, application No. 13/650,600, which is a as well as to compounds or constructs, and in particular continuation-in-part of application No. proteins and polypeptides, that comprise or essentially con PCT/EP2012/055499, filed on Mar. 28, 2012. sist of one or more such amino acid sequences. The inven tion also relates to nucleic acids encoding Such amino acid (60) Provisional application No. 60/875,860, filed on Dec. sequences and; to methods for preparing such amino acid 19, 2006, provisional application No. 61/053,847, sequences and polypeptides; to host cells expressing or filed on May 16, 2008, provisional application No. capable of expressing Such amino acid sequences or poly 61/102,142, filed on Oct. 2, 2008, provisional peptides; to compositions, and in particular to pharmaceu application No. 61/468,250, filed on Mar. 28, 2011, tical compositions, that comprise Such amino acid provisional application No. 61/540.272, filed on Sep. sequences, polypeptides, nucleic acids and/or host cells; and 28, 2011, provisional application No. 61/600,263, to uses of Such amino acid sequences or polypeptides, filed on Feb. 17, 2012. nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. (51) Int. C. C07K I6/46 (2006.01) C07K 6/28 (2006.01) 4 Claims, 3 Drawing Sheets US 9,512.236 B2 Page 2 (56) References Cited Halaby et al., The immunoglobulin fold family: Sequence analysis and 3D structure comparisons. Protein Eng. Jul. 1999; 12(7):563-71. Hassaine et al., Semliki Forest virus vectors for overexpression of FOREIGN PATENT DOCUMENTS 101 G protein-coupled receptors in mammalian host cells. Protein JP 2010-500876 A 1, 2010 Expr Purif. Feb. 2006:45(2):343-51. Epub Jul. 11, 2005. JP 2010-5069 12 A 3, 2010 Hoffman et al., A biosensor assay for studying ligand-membrane WO WO 91/O1743 A1 2, 1991 receptor interactions: binding of antibodies and HIV-1 Env to WO WO99/50461 A1 10, 1999 chemokine receptors. Proc Natl Acad Sci U S A. Oct. 10, WO WO O1/45746 A2 6, 2001 WO WO O2/O76489 A1 10, 2002 2000:97(21): 11215-20. WO WO 03/050531 A2 6, 2003 Holliger et al., Engineered antibody fragments and the rise of single WO WO 03/0668.30 A2 8, 2003 domains. Nat Biotechnol. Sep. 2005:23(9): 1126-36. WO WO 2004/041867 A2 5, 2004 Holt et al., Domain antibodies: proteins for therapy. Trends WO WO 2004/051268 A1 6, 2004 Biotechnol. Nov. 2003:21(11):484-90. WO WO 2004/064595 A2 8, 2004 Hoogenboom et al., Selection-dominant and nonaccessible epitopes WO WO 2004/106377 A1 12/2004 on cell-surface receptors revealed by cell-panning with a large WO WO 2005/O18629 3, 2005 phage antibody library. Eur J. Biochem. Mar. 1999:260(3):774-84. WO WO 2005/O19824 3, 2005 WO WO 2005/044792 A2 5, 2005 Hoogenboom, Selecting and screening recombinant antibody librar WO WO 2006/003388 A2 1, 2006 ies. Nat Biotechnol. Sep. 2005:23(9): 1105-16. WO WO 2006/03O220 A1 3, 2006 Houamed et al., Cloning, expression, and gene structure of a G WO WO 2006/038O27 A2 4/2006 protein-coupled glutamate receptor from rat brain. Science. May 31, WO WO 2006/047417 A2 5, 2006 1991:252(5010): 1318-21. WO WO 2006/089141 A2 8, 2006 Hovius et al., Characterization of a mouse serotonin 5-HT3 receptor WO WO 2006, 116319 A2 11/2006 purified from mammalian cells. J Neurochem. Feb. 1998:70(2):824 WO WO 2007/042289 A2 4/2007 34. WO WO 2007/051063 A2 5/2007 WO WO 2007.11867O A1 10, 2007 Howard et al., Orphan G-protein-coupled receptors and natural WO WO 2008/028977 A2 3, 2008 ligand discovery. Trends Pharmacol Sci. Mar. 2001:22(3): 132-40. WO WO 2008/0485.19 A2 4/2008 Hutchings et al., Therapeutic antibodies directed at G protein WO WO 2008/068280 A1 6, 2008 coupled receptors. MAbs. Nov.-Dec. 2010;2(6):594-606. Epub Nov. WO WO 2009,1385.19 A1 11, 2009 1, 2010. WO WO 2010/0101.19 A1 1, 2010 Jacoby et al., The 7TM G-protein-coupled receptor target family. WO WO 2010/043650 A2 4/2010 ChemMedChem. Aug. 2006;1(8):761-82. WO WO 2010/0701.45 A2 6, 2010 Jähnichen et al., CXCR4 nanobodies (VHH-based single variable WO WO 2010, 141986 A1 12, 2010 domains) potently inhibit chemotaxis and HIV-1 replication and WO WO 2011 117423 A1 9, 2011 mobilize stem cells. Proc Natl Acad Sci U S A. Nov. 23, 2010; 107(47):20565-70. Epub Nov. 8, 2010. OTHER PUBLICATIONS Kenakin, Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol. Jan. 2004:65(1):2-11. André et al., Enhancing functional production of G protein-coupled Kenakin, Principles: receptor theory in pharmacology. Trends Pharmacol Sci. Apr. 2004:25(4): 186-92. receptors in Pichia pastoris to levels required for structural studies Kiefer. In vitro folding of alpha-helical membrane proteins. via a single expression screen. Protein Sci. May 2006:15(5): 1115 Biochim Biophys Acta. Feb. 17, 2003; 1610(1):57-62. 26. Epub Apr. 5, 2006. Kim et al., Enhancement of colorectal tumor targeting using a novel Baribaud et al., Antigenically distinct conformations of CXCR4. J biparatopic monoclonal antibody against carcinoembryonic antigen Virol. Oct. 2001:75(19):8957- 67. in experimental radioimmunoguided Surgery. Int J Cancer. Feb. 1. Bednarek et al., Ligands of the melanocortin receptors, 2002-2003 2002;97(4): 542-7. update. Expert Opin Ther Patents. 2004;14(3):327-336. Lagane et al., CXCR4 dimerization and beta-arrestin-mediated Binz et al., Engineering novel binding proteins from nonim signaling account for the enhanced chemotaxis to CXCL 12 in munoglobulin domains. Nat Biotechnol. Oct. 2005:23(10): 1257-68. WHIM syndrome. Blood. Jul. 1, 2008:112(1):34-44. doi:10.1182/ Carnec et al., Anti-CXCR4 monoclonal antibodies recognizing blood-2007-07-102103. Epub Apr. 24, 2008. overlapping epitopes differ significantly in their ability to inhibit Lieby et al., The clonal analysis of anticardiolipin antibodies in a entry of human immunodeficiency virus type 1. J Virol. Feb. single patient with primary antiphospholipid syndrome reveals an 2005:79(3):1930-3. extreme antibody heterogeneity. Blood. Jun. 15, 2001:97(12):3820 Coutts et al., Localisation of cannabinoid CB(1) receptor 8. immunoreactivity in the guinea pig and rat myenteric plexus. J Lundstrom et al., Structural genomics on membrane proteins: Comp Neurol. Jul. 8, 2002:448(4):410-22.
Load more

Recommended publications
  • Gene Expression Polarization
    Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression This information is current as of September 27, 2021. Fernando O. Martinez, Siamon Gordon, Massimo Locati and Alberto Mantovani J Immunol 2006; 177:7303-7311; ; doi: 10.4049/jimmunol.177.10.7303 http://www.jimmunol.org/content/177/10/7303 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2006/11/03/177.10.7303.DC1 Material http://www.jimmunol.org/ References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/177/10/7303.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 Fernando O.
    [Show full text]
  • Single-Cell Rnaseq Reveals Seven Classes of Colonic Sensory Neuron
    Gut Online First, published on February 26, 2018 as 10.1136/gutjnl-2017-315631 Neurogastroenterology ORIGINAL ARTICLE Gut: first published as 10.1136/gutjnl-2017-315631 on 26 February 2018. Downloaded from Single-cell RNAseq reveals seven classes of colonic sensory neuron James R F Hockley,1,2 Toni S Taylor,1 Gerard Callejo,1 Anna L Wilbrey,2 Alex Gutteridge,2 Karsten Bach,1 Wendy J Winchester,2 David C Bulmer,1 Gordon McMurray,2 Ewan St John Smith1 ► Additional material is ABSTRact pathways to the central nervous system (CNS).1 In published online only. To view Objective Integration of nutritional, microbial and the colorectum, sensory innervation is organised please visit the journal online (http:// dx. doi. org/ 10. 1136/ inflammatory events along the gut-brain axis can alter into two main pathways: thoracolumbar (TL) spinal gutjnl- 2017- 315631). bowel physiology and organism behaviour. Colonic afferents projecting via the lumbar splanchnic sensory neurons activate reflex pathways and give nerve (LSN) and lumbosacral (LS) spinal afferents 1Department of Pharmacology, University of Cambridge, rise to conscious sensation, but the diversity and projecting via the pelvic nerve (PN) that are respon- Cambridge, UK division of function within these neurons is poorly sible for transducing conscious sensations of full- 2Neuroscience and Pain understood. The identification of signalling pathways ness, discomfort, urgency and pain, in addition to Research Unit, Pfizer, contributing to visceral sensation is constrained by a reflex actions.2 Cambridge, UK paucity of molecular markers. Here we address this by Visceral sensory afferents act to maintain many comprehensive transcriptomic profiling and unsupervised aspects of GI physiology, such as continence and Correspondence to James R F Hockley, Department clustering of individual mouse colonic sensory neurons.
    [Show full text]
  • F2RL2 Antibody Cat
    F2RL2 Antibody Cat. No.: 56-323 F2RL2 Antibody F2RL2 Antibody immunohistochemistry analysis in formalin fixed and paraffin embedded human heart tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Human This F2RL2 antibody is generated from rabbits immunized with a KLH conjugated IMMUNOGEN: synthetic peptide between 21-50 amino acids from the N-terminal region of human F2RL2. TESTED APPLICATIONS: IHC-P, WB For WB starting dilution is: 1:1000 APPLICATIONS: For IHC-P starting dilution is: 1:10~50 PREDICTED MOLECULAR 43 kDa WEIGHT: September 25, 2021 1 https://www.prosci-inc.com/f2rl2-antibody-56-323.html Properties This antibody is purified through a protein A column, followed by peptide affinity PURIFICATION: purification. CLONALITY: Polyclonal ISOTYPE: Rabbit Ig CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: Supplied in PBS with 0.09% (W/V) sodium azide. CONCENTRATION: batch dependent Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies STORAGE CONDITIONS: care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: F2RL2 Proteinase-activated receptor 3, PAR-3, Coagulation factor II receptor-like 2, Thrombin ALTERNATE NAMES: receptor-like 2, F2RL2, PAR3 ACCESSION NO.: O00254 GENE ID: 2151 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References Coagulation factor II (thrombin) receptor-like 2 (F2RL2) is a member of the large family of 7-transmembrane-region receptors that couple to guanosine-nucleotide-binding proteins.
    [Show full text]
  • Cognition and Steroidogenesis in the Rhesus Macaque
    Cognition and Steroidogenesis in the Rhesus Macaque Krystina G Sorwell A DISSERTATION Presented to the Department of Behavioral Neuroscience and the Oregon Health & Science University School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2013 School of Medicine Oregon Health & Science University CERTIFICATE OF APPROVAL This is to certify that the PhD dissertation of Krystina Gerette Sorwell has been approved Henryk Urbanski Mentor/Advisor Steven Kohama Member Kathleen Grant Member Cynthia Bethea Member Deb Finn Member 1 For Lily 2 TABLE OF CONTENTS Acknowledgments ......................................................................................................................................................... 4 List of Figures and Tables ............................................................................................................................................. 7 List of Abbreviations ................................................................................................................................................... 10 Abstract........................................................................................................................................................................ 13 Introduction ................................................................................................................................................................. 15 Part A: Central steroidogenesis and cognition ............................................................................................................
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Supplementary Data
    Supplemental Data A novel mouse model of X-linked nephrogenic diabetes insipidus: Phenotypic analysis and therapeutic implications Jian Hua Li, Chung-Lin Chou, Bo Li, Oksana Gavrilova, Christoph Eisner, Jürgen Schnermann, Stasia A. Anderson, Chu-Xia Deng, Mark A. Knepper, and Jürgen Wess Supplemental Methods Metabolic cage studies. Animals were maintained in mouse metabolic cages (Hatteras Instruments, Cary, NC) under controlled temperature and light conditions (12 hr light and dark cycles). Mice received a fixed daily ration of 6.5 g of gelled diet per 20 g of body weight per day. The gelled diet was composed of 4 g of Basal Diet 5755 (Test Diet, Richmond, IN), 2.5 ml of deionized water, and 65 mg agar. Preweighted drinking water was provided ad libitum during the course of the study. Mice were acclimated in the metabolic cages for 1-2 days. Urine was collected under mineral oil in preweighted collection vials for successive 24 hr periods. Analysis of GPCR expression in mouse IMCD cells via TaqMan real-time qRT-PCR. Total RNA prepared from mouse IMCD tubule suspensions was reverse transcribed as described under Experimental Procedures. Tissues from ten 10-week old C57BL/6 WT mice were collected and pooled for each individual experiment. cDNA derived from 640 ng of RNA was mixed with an equal volume of TaqMan gene expression 2 x master mix (Applied Biosystems, Foster City, CA). 100 μl-aliquots of this mixture (corresponding to 80 ng of RNA) were added to each of the 8 fill ports of a 384-well plate of a mouse GPCR array panel (Applied Biosystems).
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • The 'C3ar Antagonist' SB290157 Is a Partial C5ar2 Agonist
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.01.232090; this version posted August 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The ‘C3aR antagonist’ SB290157 is a partial C5aR2 agonist Xaria X. Li1, Vinod Kumar1, John D. Lee1, Trent M. Woodruff1* 1School of Biomedical Sciences, The University of Queensland, St Lucia, 4072 Australia. * Correspondence: Prof. Trent M. Woodruff School of Biomedical Sciences, The University of Queensland, St Lucia, 4072 Australia. Ph: +61 7 3365 2924; Fax: +61 7 3365 1766; E-mail: [email protected] Keywords: Complement C3a, C3aR, SB290157, C5aR1, C5aR2 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.01.232090; this version posted August 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abbreviations used in this article: BRET, bioluminescence resonance energy transfer; BSA, bovine serum albumin; C3aR, C3a receptor C5aR1, C5a receptor 1; CHO-C3aR, Chinese hamster ovary cells stably expressing C3aR; CHO-C5aR1, Chinese hamster ovary cells stably expressing C5aR1; DMEM, Dulbecco's Modified Eagle's Medium; ERK1/2, extracellular signal-regulated kinase 1/2; FBS, foetal bovine serum; HEK293, human embryonic kidney 293 cells; HMDM, human monocyte-derived macrophage; i.p., intraperitoneal; i.v., intravenous; rhC5a, recombinant human C5a; RT, room temperature; S.E.M.
    [Show full text]
  • BD Biosciences New RUO Reagents - November 2020
    BD Biosciences New RUO reagents - November 2020 Reactivity Description Format Clone Size Cat. number Hu CD133 FITC W6B3C1 100µg 567029 Hu CD133 FITC W6B3C1 25µg 567033 Hu CD39 PE A1/CD39 100Tst 567156 Hu CD39 PE A1/CD39 25Tst 567157 Hu KIR2DL1/S1/S3/S5 PE HP-MA4 100Tst 567158 Hu KIR2DL1/S1/S3/S5 PE HP-MA4 25Tst 567159 Hu IL-22 Alexa Fluor® 647 MH22B2 100µg 567160 Hu IL-22 Alexa Fluor® 647 MH22B2 25µg 567161 Hu CD99 R718 TU12 50µg 751651 Hu CD161 R718 DX12 50µg 751652 Hu CD116 R718 HGMCSFR-M1 50µg 751653 Hu HLA-G R718 87G 50µg 751670 Hu CD27 R718 O323 50µg 751686 Hu CD80 (B7-1) R718 2D10.4 50µg 751737 Hu Integrin αvβ5 R718 ALULA 50µg 751738 Hu CD266 (Tweak-R) R718 ITEM-4 50µg 751739 Hu ErbB3 (HER-3) R718 SGP1 50µg 751799 Hu TCR Vβ5.1 R718 LC4 50µg 751816 Hu CD123 (IL-3Ra) R718 6H6 50µg 751844 Hu CD1a R718 SK9 50µg 751847 Hu CD20 R718 L27 50µg 751849 Hu Disial GD2 R718 14.G2A 50µg 751851 Reactivity Description Format Clone Size Cat. number Hu CD71 R718 L01.1 50µg 751853 Hu CD278 (ICOS) R718 DX29 50µg 751854 Hu B7-H4 R718 MIH43 50µg 751857 Hu CD53 R718 HI29 50µg 751858 Hu CD197 (CCR7) R718 2-L1-A 50µg 751859 Hu CD197 (CCR7) R718 3D12 50µg 751861 Hu CD31 R718 L133.1 50µg 751863 Hu EGF Receptor R718 EMAB-134 50µg 751864 Hu CD8b R718 2ST8.5H7 50µg 751867 Hu CD31 R718 MBC 78.2 50µg 751869 Hu CD162 R718 KPL-1 50µg 751873 Hu CD24 R718 ML5 50µg 751874 Hu CD159C (NKG2C) R718 134591 50µg 751876 Hu CD169 (Siglec-1) R718 7-239 50µg 751877 Hu CD16b R718 CLB-GRAN11.5 50µg 751880 Hu IgM R718 UCH-B1 50µg 751881 Hu CD275 R718 2D3/B7-H2 50µg 751883 Hu CD307e
    [Show full text]
  • Integrative Analysis of Mirna–Mrna Network in High Altitude Retinopathy by Bioinformatics Analysis
    Bioscience Reports (2021) 41 BSR20200776 https://doi.org/10.1042/BSR20200776 Research Article Integrative analysis of miRNA–mRNA network in high altitude retinopathy by bioinformatics analysis Tong Su1,2,*, Chufeng Gu1,2,*,DejiDraga3,*, Chuandi Zhou1,2, Thashi Lhamo3, Zhi Zheng1,2 and Qinghua Qiu1,2,3 1Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China; 2National Clinical Research Center for Eye Downloaded from http://portlandpress.com/bioscirep/article-pdf/41/1/BSR20200776/902020/bsr-2020-0776.pdf by guest on 26 September 2021 Diseases; Shanghai Key Laboratory of Ocular Fundus Diseases; Shanghai Engineering Center for Visual Science and Photomedicine; Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, P.R. China; 3Department of Ophthalmology, Shigatse People’s Hospital, Shigatse, Xizang, P.R. China Correspondence: Qinghua Qiu ([email protected]) or Zhi Zheng ([email protected]) High-altitude retinopathy (HAR) is an ocular manifestation of acute oxygen deficiency at high altitudes. Although the pathophysiology of HAR has been revealed by many studies in recent years, the molecular mechanism is not yet clear. Our study aimed to systemati- cally identify the genes and microRNA (miRNA) and explore the potential biomarkers asso- ciated with HAR by integrated bioinformatics analysis. The mRNA and miRNA expression profiles were obtained from the Gene Expression Omnibus database. We performed Gene Ontology functional annotations and Kyoto Encyclopedia of Genes and Genomes path- way analysis. Potential target gene analysis and miRNA–mRNA network analysis were also conducted. Quantitative RT-PCR (qRT-PCR) was used to validate the results of the bioinfor- matics analysis.
    [Show full text]
  • Conformational Dynamics Between Transmembrane Domains And
    RESEARCH ARTICLE Conformational dynamics between transmembrane domains and allosteric modulation of a metabotropic glutamate receptor Vanessa A Gutzeit1, Jordana Thibado2, Daniel Starer Stor2, Zhou Zhou3, Scott C Blanchard2,3,4, Olaf S Andersen2,3, Joshua Levitz2,4,5* 1Neuroscience Graduate Program, Weill Cornell Graduate School of Medical Sciences, New York, United States; 2Physiology, Biophysics and Systems Biology Graduate Program, Weill Cornell Graduate School of Medical Sciences, New York, United States; 3Department of Physiology and Biophysics, Weill Cornell Medicine, New York, United States; 4Tri-Institutional PhD Program in Chemical Biology, New York, United States; 5Department of Biochemistry, Weill Cornell Medicine, New York, United States Abstract Metabotropic glutamate receptors (mGluRs) are class C, synaptic G-protein-coupled receptors (GPCRs) that contain large extracellular ligand binding domains (LBDs) and form constitutive dimers. Despite the existence of a detailed picture of inter-LBD conformational dynamics and structural snapshots of both isolated domains and full-length receptors, it remains unclear how mGluR activation proceeds at the level of the transmembrane domains (TMDs) and how TMD-targeting allosteric drugs exert their effects. Here, we use time-resolved functional and conformational assays to dissect the mechanisms by which allosteric drugs activate and modulate mGluR2. Single-molecule subunit counting and inter-TMD fluorescence resonance energy transfer *For correspondence: measurements in living cells
    [Show full text]
  • G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes
    Int. J. Mol. Sci. 2014, 15, 1112-1142; doi:10.3390/ijms15011112 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes Benoît T. Roux 1 and Graeme S. Cottrell 2,* 1 Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK; E-Mail: [email protected] 2 Reading School of Pharmacy, University of Reading, Reading RG6 6UB, UK * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-118-378-7027; Fax: +44-118-378-4703. Received: 4 December 2013; in revised form: 20 December 2013 / Accepted: 8 January 2014 / Published: 16 January 2014 Abstract: G protein-coupled receptors (GPCRs) are important cell signaling mediators, involved in essential physiological processes. GPCRs respond to a wide variety of ligands from light to large macromolecules, including hormones and small peptides. Unfortunately, mutations and dysregulation of GPCRs that induce a loss of function or alter expression can lead to disorders that are sometimes lethal. Therefore, the expression, trafficking, signaling and desensitization of GPCRs must be tightly regulated by different cellular systems to prevent disease. Although there is substantial knowledge regarding the mechanisms that regulate the desensitization and down-regulation of GPCRs, less is known about the mechanisms that regulate the trafficking and cell-surface expression of newly synthesized GPCRs. More recently, there is accumulating evidence that suggests certain GPCRs are able to interact with specific proteins that can completely change their fate and function. These interactions add on another level of regulation and flexibility between different tissue/cell-types.
    [Show full text]